EVALUATE SAFETY & TOLERABILITY OF DMP 543 FOR ALZHEIMERS PATIENTS

评估安全性

• 批准号: 6264699
• 负责人: CHRISTOPHER H VAN DYCK
• 金额: $ 3.45万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6264699
• 关键词: Alzheimer's disease; acetylcholine; brain disorder chemotherapy; clinical research; dosage; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; neurotransmitter agonist

The purpose of the study is to determine the safety of DMP 543 during multiple dosing in patients with Alzheimer's disease. Identification of a minimum intolerable dose as defined by adverse experiences will be subject to the limitation of individual peak plasma concentrations, not to exceed 5.0 ng/ml during dosing. The study will be a single-site, placebo-controlled escalating multiple dose, inpatient and outpatient study. Yale will be the only study site. Study was terminated in November 1998 by Industry Sponsor.

该研究的目的是确定阿尔茨海默氏病多种剂量期间DMP 543的安全性。 通过不利经历定义的最低无法忍受的剂量的鉴定将受到单个峰血浆浓度的限制，在给药期间不超过5.0 ng/ml。 这项研究将是一项单位，安慰剂对照的多种剂量，住院和门诊研究。 耶鲁大学将是唯一的学习地点。 研究于1998年11月由行业赞助商终止。